Martin Schmieg

Martin E.
Schmieg is the founder of Soar Ventures, founded in 2013, serving as General Manager since its founding.
Mr. Schmieg was the founder of ClearIt LLC, founded in 2013, and served as President, Chief Executive Officer & Director from 2013 to 2021.
Mr. Schmieg was the founder of Clear Intradermal Technologies, Inc., founded in 2003, and served as Chief Financial & Technology Officer from 2003 to 2021.
Current jobs include Chief Executive Officer at TrueBinding, Inc., Independent Director at BriaCell Therapeutics Corp.
since 2020, Chief Financial Officer & Director at Sapientia Pharmaceuticals, Inc., Managing Director at DIgSILENT Holding GmbH, Independent Director at BriaPro Therapeutics Corp., and Investment Advisor at Boutique Venture Partners LLC.
Former jobs include President & Chief Executive Officer at Freedom2, Inc. from 2006 to 2009; Chairman, President & Chief Executive Officer at PharmaCyte Biotech, Inc. from 2009 to 2010; Chief Financial Officer & Director at Rokk3r, Inc. in 2017; Independent Director at BriaCell Therapeutics Corp.
from 2016 to 2019; Chief Financial Officer at Sirna Therapeutics, Inc. from 2004 to 2005; Chief Financial Officer at Fibrocell Science, Inc. from 2005 to 2006; Chief Financial Officer at Advanced Bionics Corp.
from 2003 to 2004; Chief Financial Officer at Isolagen Technologies, Inc. from 2005 to 2006; Vice President at NeoStem, Inc. from 2012 to 2013; Vice President-Corporate Development at Caladrius Biosciences, Inc.; Chief Financial Officer at Cytometrics, Inc. from 1992 to 2000; and Chief Financial Officer at Rokk3r Labs LLC.
Education includes undergraduate studies at LaSalle University.